Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Know Your Investor: Janus Henderson Group Plc (April’25 Edition)
Know Your Investor: Janus Henderson Group Plc (April’25 Edition)
Shots:    Welcome to the 2025 series of Know Your Investor, featuring top venture capital firms focused on healthcare.  This edition highlights Janus Henderson Group Plc, a global investment firm managing approximately $378.7B in assets across Equities, Fixed Income, Multi-Asset, and Alternatives.  In 2024, the firm invested $5.36B across six funding rounds, adding 39 healthcare and…
April 3, 2025
PharmaShots’ Key Highlights of First Quarter 2025
Shots:   Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B   The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata  PharmaShots brings…
April 1, 2025
Disease of the Month – Lennox-Gastaut syndrome (LGS)
Disease of the Month – Lennox-Gastaut syndrome (LGS)
Shots:  Lennox-Gastaut syndrome (LGS) is a severe childhood-onset epileptic condition characterized by repeated seizures   Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and patient advocacy groups involved in enhancing patient care. Additionally, we are highlighting the key industry players advancing treatments for LGS   For a detailed epilepsy…
March 26, 2025
New Drug Designations - February 2025
New Drug Designations – February 2025
Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA   The February 2025 report covers designations granted to 53 drugs and 4 medical devices, spanning 16 small molecules, 14 biologics, 18 cell and gene therapies & 4 medical devices among…
March 25, 2025
Know Your Investor: Perceptive Advisors (March’25 Edition)
Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025
EMA Marketing Authorization of New Drugs in February 2025
EMA Marketing Authorization of New Drugs in February 2025
Shots:    The EMA’s CHMP has granted positive opinions and approvals to 5 Biologics and 2 New Chemical Entities in February 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Merck’s Welireg to treat Von Hippel-Lindau & Renal Cell Carcinoma    PharmaShots has compiled a list of 6 drugs…
March 18, 2025
The US FDA New Drug Approvals in February 2025
The US FDA New Drug Approvals in February 2025
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2025       The US FDA has approved a total of 3 new drug including 3 new molecular entities and leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was Abbvie’s Emblaveo securing approval for…
March 11, 2025
A Complete Account of EMA Approvals in 2024
A Complete Account of EMA Approvals in 2024
Shots:   In 2024, EMA approved around 53 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, vaccines, diagnostic agents, pneumology, nephrology, hepatology, ophthalmology, and endocrinology   PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, &…
March 6, 2025
Key Biosimilars Events of February 2025
Key Biosimilars Events of February 2025
Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         A major highlight was the Samsung Bioepis & Teva Partners to Commercialize…
March 4, 2025
New Drug Designations - January 2025
New Drug Designations – January 2025
Shots:    PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA  The January 2025 report covers designations granted to 53 drugs and 9 medical devices, spanning 18 small molecules, 13 biologics, 13 cell and gene therapies & 9 medical devices among…
February 28, 2025
Load more